DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Reversal of refractory septic shock with drotrecogin alpha (activated).

Author(s): Vieillard-Baron A, Caille V, Charron C, Belliard G, Aegerter P, Page B, Jardin F

Affiliation(s): Medical Intensive Care Unit, Service de Reanimation Medicale, Centre Hospitalier Universitaire Ambroise Pare, 9 Avenue Charles de Gaulle, 92104, Boulogne Cedex, France. antoine.vieillard-baron@apr.aphp.fr

Publication date & source: 2009-07, Intensive Care Med., 35(7):1204-9. Epub 2009 Jun 16.

OBJECTIVE: We previously reported that early continuous veno-venous hemodiafiltration (CVVHDF) enables rapid identification of a subgroup of patients with "refractory" septic shock and a 100% risk of death. The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. METHOD: Prospective observational study in a medical intensive-care unit of a University Hospital. Twenty-three patients with refractory septic shock were included. "Refractory" shock was defined as persistent circulatory failure despite adequate circulatory support, associated with persisting lactic acidosis despite early CVVHDF. Response to CVVDHF was assessed after 6 h of this continuous procedure. Patients selected by this strategy received DrotAA infusion for four days. RESULTS: The 28-day mortality rate of the 23 patients was 39%. No difference was observed at inclusion between survivors and nonsurvivors. In patients who finally survived, 12 h of DrotAA infusion was associated with a significant decrease in lactic acidosis and in norepinephrine dose. CONCLUSION: DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017